

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-21. (Canceled)

22. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3 and comprises:

an H chain V region having the amino acid sequence represented by SEQ ID NO:9; and

an L chain V region having the amino acid sequence represented by SEQ ID NO:54

~~The antibody conjugate according to claim 1, wherein the humanized antibody comprises:~~

~~the H chain V region having the amino acid sequence represented by SEQ ID NO:9; and~~

~~the L chain V region having the amino acid sequence represented by SEQ ID NO:54.~~

23. (Currently Amended) An antibody conjugate, comprising a humanized antibody
~~The antibody conjugate according to claim 1, wherein the humanized antibody is an~~

~~antibody~~-produced by a transformant KM8871 (FERM BP-6790) or an antibody fragment thereof which is conjugated with therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3.

Claims 24-31. (Canceled)

32. (Currently Amended) The antibody conjugate according to claim 22[[1]], wherein the antibody fragment comprises:

the H chain V region having the amino acid sequence represented by SEQ ID NO:9; and

the L chain V region having the amino acid sequence represented by SEQ ID NO:54.

Claims 33-35. (Canceled)

36. (Currently Amended) The antibody conjugate according to claim [[1]]22, wherein the therapeutic agent is a cytokine.

37. (Previously Presented) The antibody conjugate according to claim 36, wherein the cytokine is human interleukin-2 (hIL-2).

Claims 38-39. (Canceled)

40. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to

ganglioside GD3, ~~The antibody conjugate according to claim 37, wherein the antibody conjugate comprises a humanized antibody is produced by transformant KM8871 (FERM BP-6790) and the therapeutic agent is hIL-2.~~

41. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with ~~The antibody conjugate according to claim 37, wherein the antibody conjugated with hIL-2 comprises:~~

the, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3 and comprises:

an H chain V region having the amino acid sequence represented by SEQ ID NO:9;
and

[[the]]an L chain V region having the amino acid sequence represented by SEQ ID NO:54,

wherein the H chain V region conjugated with hIL-2 has the amino acid sequence represented by SEQ ID NO:53.

Claims 42-47. (Canceled)

48. (Previously Presented) A humanized antibody or an antibody fragment thereof which specifically binds to ganglioside GD3 and comprises:

an H chain V region having the amino acid sequence represented by SEQ ID NO:9;
and

an L chain V region having the amino acid sequence in which at least one or more amino acid residue selected from 41st position Gly, 44th position Pro, 83rd position Phe and 87th position Tyr represented by SEQ ID NO:10 is replaced with Asp, Val, Ile and Phe, respectively.

Claims 49-57. (Canceled)

58. (Currently Amended) The humanized antibody KM8871 or the antibody fragment thereof according to claim 48 or 65 ~~or 63~~, wherein the humanized antibody is an antibody produced by a transformant KM8871 (FERM BP-6790).

Claims 59-61. (Canceled)

62. (Currently Amended) A transformant KM8871 (FERM BP-6790) which produces the humanized antibody according to claim 48 or 65 ~~or 63~~.

Claims 63-64. (Canceled)

65. (Currently Amended) The humanized antibody or the antibody fragment thereof according to claim 48 ~~or 63~~, wherein the antibody fragment comprises:

the H chain V region having the amino acid sequence represented by SEQ ID NO:9; and

the L chain V region having the amino acid sequence represented by SEQ ID NO:54.

Claims 66-68. (Canceled)

69. (Previously Presented) The antibody conjugate of claim 40, wherein the antibody conjugate is an antibody conjugate produced by a transformant KM8871hIL2 (FERM BP-6791).